ketamine implant (SP-26) / Silo Pharma - LARVOL DELTA

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia (GlobeNewswire) - "Silo Pharma...today announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously. The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia...The launch of our non-GLP study in December 2024 marked the first small animal testing of SP-26, a key preclinical milestone. Implantation (dosing) was completed in the first week of January 2025 and no animals experienced serious side effects or discomfort. Absorption, distribution, metabolism, and excretion (ADME) testing is nearing completion and final safety, and pharmacokinetic reports are expected in March 2025."

Preclinical • Fibromyalgia • Pain

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic (GlobeNewswire) - "Silo Pharma...announced a new agreement with Sever Pharma Solutions for scale-up extrusion of the Company’s SP-26 ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. In addition, Sever Pharma Solutions will continue with analytical testing of the ketamine hydrochloride (ketamine HCL) polymer implants using the optimal time-released, dose-controlled formulation previously selected by Silo for continuing pre-clinical studies."

Licensing / partnership • Fibromyalgia • Pain

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic (GlobeNewswire) - "Silo Pharma, Inc...announced its entry into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. The research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability."

Licensing / partnership • Preclinical • CNS Disorders • Fibromyalgia